{"id":"NCT03201900","sponsor":"Eisai Co., Ltd.","briefTitle":"Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)","officialTitle":"A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Eefficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures) (FREEDOM Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-28","primaryCompletion":"2019-02-28","completion":"2020-07-27","firstPosted":"2017-06-28","resultsPosted":"2020-02-25","lastUpdate":"2021-08-05"},"enrollment":91,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"E2007","otherNames":["Perampanel","Fycompa","2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile hydrate (4:3)"]}],"arms":[{"label":"E2007","type":"EXPERIMENTAL"}],"summary":"This study is conducted to evaluate the seizure-free rate of the 26-week Maintenance Period in untreated participants with partial onset seizures (POS).","primaryOutcome":{"measure":"Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel","timeFrame":"26 weeks in Maintenance Period of 4 mg perampanel","effectByArm":[{"arm":"Perampanel","deltaMin":63,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":23},"locations":{"siteCount":38,"countries":["Japan","South Korea"]},"refs":{"pmids":["34657389"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":89},"commonTop":["Dizziness","Nasopharyngitis","Somnolence","Headache","Diarrhoea"]}}